Experimental combo aims to rev up immune system against Hard-to-Treat prostate cancer
NCT ID NCT05445609
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two drugs—vidutolimod and nivolumab—can help the immune system attack metastatic castration-resistant prostate cancer. Nivolumab blocks a protein that shuts down immune cells, while vidutolimod is designed to train those cells to target tumors. The study planned to enroll 10 men whose cancer had progressed after other treatments, but it is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vidutolimod (CMP-001) and nivolumab
- What this could lead to
- If it works, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very small, early-phase trial (only 10 participants) and is currently suspended. The treatment may not shrink tumors or improve survival, and side effects from immune therapy can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- New prostate cancer drug HRS-7525 enters first human tests
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
- Blood test aims to spot hidden cancer cells in 9 tumor types